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The kynurenine pathway (KP) is the major metabolic pathway of the essential amino acid 
tryptophan (TRP). Stimulation by inflammatory molecules, such as interferon-γ (IFN-γ), is 
the trigger for induction of the KP, driving a complex cascade of production of both neu-
roprotective and neurotoxic metabolites, and in turn, regulation of the immune response 
and responses of brain cells to the KP metabolites. Consequently, substantial evidence 
has accumulated over the past couple of decades that dysregulation of the KP and 
the production of neurotoxic metabolites are associated with many neuroinflammatory 
and neurodegenerative diseases, including Parkinson’s disease, AIDS-related dementia, 
motor neurone disease, schizophrenia, Huntington’s disease, and brain cancers. In 
the past decade, evidence of the link between the KP and multiple sclerosis (MS) has 
rapidly grown and has implicated the KP in MS pathogenesis. KP enzymes, indoleamine 
2,3-dioxygenase (IDO-1) and tryptophan dioxygenase (highest expression in hepatic 
cells), are the principal enzymes triggering activation of the KP to produce kynurenine 
from TRP. This is in preference to other routes such as serotonin and melatonin produc-
tion. In neurological disease, degradation of the blood–brain barrier, even if transient, 
allows the entry of blood monocytes into the brain parenchyma. Similar to microglia 
and macrophages, these cells are highly responsive to IFN-γ, which upregulates the 
expression of enzymes, including IDO-1, producing neurotoxic KP metabolites such as 
quinolinic acid. These metabolites circulate systemically or are released locally in the 
brain and can contribute to the excitotoxic death of oligodendrocytes and neurons in 
neurological disease principally by virtue of their agonist activity at N-methyl-d-aspartic 
acid receptors. The latest evidence is presented and discussed. The enzymes that 
control the checkpoints in the KP represent an attractive therapeutic target, and conse-
quently several KP inhibitors are currently in clinical trials for other neurological diseases, 
and hence may make suitable candidates for MS patients. Underpinning these drug 
discovery endeavors, in recent years, several advances have been made in how KP 
metabolites are assayed in various biological fluids, and tremendous advancements 
have been made in how specimens are imaged to determine disease progression and 
involvement of various cell types and molecules in MS.
Keywords: kynurenine pathway, neuroinflammation, neurodegenerative disease, multiple sclerosis, multiphoton 
microscopy
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RATiONALe FOR iNvOLveMeNT  
OF KP iN MS
Multiple sclerosis (MS) is a chronic, inflammatory demyelinating 
disorder of the central nervous system (CNS) whose etiology 
remains multifactorial and the subject of intense debate. This 
complexity arises from the several distinct demyelinating dis-
orders of varying severity that are grouped under the general 
definition of MS. This indicates that definitive initial triggers 
(genetic, environmental, and others) that initiate episodes of 
autoimmune demyelination have yet to be identified, and that 
different mechanisms could contribute to lesion formation and 
tissue injury (1). MS is mediated by pathogenic T cells that are 
autoreactive against myelin antigens and coincides with broader 
neurodegenerative processes. Following trafficking into the brain 
via a compromised blood–brain barrier (BBB), T cells target 
and attack the myelin sheath of oligodendrocytes, the myelin-
forming cells of the CNS, which envelop central neurons and 
axons (2). The inflammatory plaque is the pathological hallmark 
of MS and can be identified using magnetic resonance imaging 
(MRI) or histopathologically (3). MS represents one of the most 
common causes of chronic neurological disabilities in young 
people, and its course is greatly variable (4). MS is subclassified 
into at least four distinguishable categories based on the course 
of disease. Approximately 85% of MS patients have a disease 
course that is marked by episodes (relapses) of neurological 
symptoms followed by remission periods where symptoms 
recover or disappear. This relapse-remitting MS form (RRMS) 
is often followed by secondary progressive MS (SPMS), where 
the disease progresses to constant neurological deterioration with 
no period of remission. Primary progressive MS (PPMS) affects 
around 10% of patients who present with gradually increasing 
neurological disability from the onset. Similarly, progressive-
relapsing MS (PRMS), which at 5% incidence is the rarest form, 
is also progressive, however, displays intermittent episodes of 
exacerbated symptoms. There are currently few drugs available to 
treat the progressive forms of disease (PPMS, SPMS, and PRMS), 
and therapies for RRMS have little efficacy in treating disability 
and neurodegeneration (5, 6).
Although an inflammatory aspect of the disease is 
clear – characterized by the presence of infiltrating macrophages 
and activated microglia around lesions (7, 8) as well as the 
autoimmune component arising from lymphocyte entry into 
the CNS, the role of other cells, such as monocytes, and other 
pathways that can further compromise oligodendrocyte health 
and contribute to the pathology of MS is increasingly being 
recognized by a theory of MS as a neurodegenerative disease 
with an autoimmune component (9). The question of whether 
inflammation leads to neurodegeneration or whether these are 
two different processes is currently unclear. The kynurenine 
pathway (KP) is activated in number of inflammatory and 
neurodegenerative diseases, including MS, and as such rep-
resents a common pathological mechanism highly relevant to 
our understanding of MS pathology (10). While the KP is the 
principal means by which tryptophan (TRP) is catabolized, it 
also leads to the production of several potent immunomodula-
tory and neuroactive intermediates, collectively called the 
kynurenines. Dysregulation of many of the enzymatic steps in 
the KP can favor the production of neurotoxic vs. neuroprotec-
tive metabolites (11). Monocytes, in particular, can be activated 
by high levels of inflammatory cytokines, which upregulate the 
expression of KP enzymes, favoring the production, and secre-
tion of neurotoxic metabolites such as quinolinic acid (QUIN) 
(Figure 1, red box) (12).
Dysregulation of the KP may not be the primary cause of 
MS; rather the evidence thus far suggests its involvement is 
characterized by inflammatory episodes triggering KP activation 
(particularly in monocytes), trafficking to the brain, concomitant 
TRP degradation and production of neurotoxic metabolites. 
These aspects can contribute to the pathogenesis and the disease 
course of MS by promoting brain cell dysfunction and death, 
which in turn prevent the induction of essential brain cell 
survival and repair mechanisms. This is evidenced by studies 
showing that the KP is activated in early stages of MS in patients 
and in the experimental autoimmune encephalomyelitis (EAE) 
rodent model of MS (13), while monocytes are highly present in 
MS lesions during autoimmune episodes. Moreover, differences 
in disease course and clinical activity in MS are reflected by 
changes in the levels of KP metabolites, particularly in cerebro-
spinal fluid (CSF) (see CSF: A Window to Study Dysregulation 
of KP in the Pathology of MS and KP Metabolites Correlate 
with Increased MS Severity: Potential Utility as MS Biomarkers). 
Therefore, an activated KP could compromise the effectiveness 
of MS treatments, which predominantly target the autoimmune 
component.
In this review, we focus on evidence accumulated from MS 
studies that have demonstrated a dysregulation of the KP, result-
ing in elevated levels of neurotoxic metabolites both in the plasma 
and brain parenchyma (detected in CSF), and thus contribute 
to the progression of MS pathology. We focus on the cells that 
produce these damaging metabolites (Figure  1); circulating 
monocytes (see Peripheral Blood Monocytes as a Potent Source 
of Inflammatory KP Metabolites in MS) which enter the brain 
via a compromised BBB (see The BBB Performs a Critical Role 
in Maintaining Barrier Integrity and Permeability, Which Is 
Lost in MS) and to a lesser extent endogenous brain cells; how 
these metabolites are measured by analytical sampling (see CSF: 
A Window to Study Dysregulation of KP in the Pathology of 
MS) and also the mechanisms of action of these metabolites 
(see Mechanisms of Toxicity of KP Metabolites) and how they 
cause oligodendrocyte death (see Oligodendrocytes as a Target 
Cell for Elevated Levels of KP Metabolites in MS). We also 
consider how the KP can regulate both adaptive and innate 
immune responses (see KP Influence on the Immune System), 
and how some KP metabolites can serve as potential biomarkers 
of MS progression, detailed evidence for their association with 
MS (see KP Metabolites Correlate with Increased MS Severity: 
Potential Utility as MS Biomarkers) and therapeutic interven-
tions (see Modulation of the KP as a Therapeutic Strategy in MS). 
Concurrent with this discussion, we also consider how advances 
in microscope imaging and allied techniques (see Microscope 
Imaging as a Central Tool for Advancing Knowledge of MS 
Pathology) have made a profound and ongoing contribution to 
our understanding of MS pathology.
FiguRe 1 | The kynurenine pathway of tryptophan metabolism produces neuroprotective as well as neurotoxic metabolites that can influence MS 
pathology. Neurotoxic metabolites are circled in red, and neuroprotective metabolites in green. Tryptophan (blue box) may be metabolized to serotonin and 
melatonin in multi-step sequential reactions, or alternatively is metabolized via the KP. This reaction is inhibited by 1-methyl tryptophan (1-MT) or berberine. 
Kynurenine (purple box) is the initial rate-limiting KP product of tryptophan metabolism by the enzymes indoleamine-2,3-dioxygenase (IDO-1) and tryptophan 
dioxygenase (orange box). Kynurenine is then converted via kynurenine aminotransferases (KATI/II/III) to kynurenic acid, a neuroprotective molecule as it antagonizes 
glutamate receptor-induced neurotoxicity. 3-hydroxykynurenine is produced by further metabolism of kynurenine, for which evidence is accumulating of its 
neurotoxic capability. This reaction is inhibited by Ro61-8048 or nicotinylalanine. Leflunomide (Avara®) is an immunosuppressive and anti-inflammatory drug. 
Teriflunomide is the active metabolite of leflunomide. These kynurenine analogs are effective in reducing active lesions in both rodent models and in a phase II clinical 
trial (235). Kynureninase catalyzes the conversion of 3-hydroxykynurenine to 3-hydroxyanthranilic acid. Tranilast is a synthetic anthracillic acid derivative drug with 
anti-inflammatory action (236). Sequential conversion to 2-amino-3-carboxymuconate-semialdehyde is the penultimate step leading to enzymatic production of 
(neuroprotective) picolinic acid, and the (non-enzymatic) production of the well-known neurotoxic compound quinolinic acid (QUIN). Further conversion of QUIN to 
the essential cofactor NAD+ is catalyzed by quinolinate phosphoribosyltransferase (QPRT). Dashed boxes indicate synthetic compounds, some of which are in drug 
development, that are derivatives of the KP metabolite described above.
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THe KYNuReNiNe PATHwAY
Approximately 95% of TRP is catabolized via the KP in both 
the CNS and periphery, which is thus the canonical route, while 
the remainder forms a substrate for serotonin and melatonin 
synthesis. In the KP, TRP is converted to N-formyl-l-kynurenine 
by indoleamine 2,3-dioxygenase (IDO-1/IDO-2) and tryptophan 
2,3-dioxygenase 2 (TDO); the rate-limiting enzyme in TRP degra-
dation. TDO is strongly and constitutively expressed in the liver; 
however, it is also expressed at lower levels in neurons, astrocytes, 
and endothelial cells (14, 15). Therefore, extra-hepatically, IDO-1 
is the predominant enzyme in several different cell types, including 
monocytes, macrophages, microglia, astrocytes, neurons, and in 
some stem cells. IDO-2 is structurally and enzymatically similar to 
IDO-1; however, it is thought to function as a redundant enzyme 
to IDO-1 given its basal expression in a narrow range of cell types 
(16). Recently, new evidence suggests that IDO-2 has a role in 
“self-antigen” tolerance in autoimmunity and shaping immune 
tolerance in humans [reviewed in Ref. (17)]. Proceeding along 
the KP, N-formyl-l-kynurenine is metabolized by formamidase 
to l-kynurenine (KYN), the first stable intermediate metabolite 
(Figure  1). In the CNS, ~40% of KYN is locally produced, 
whereas 60% of KYN present is absorbed from the blood (18). 
Kynurenine is a central KP metabolite, capable of being degraded 
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through three specific pathways to generate different metabolites 
[kynurenic acid (KYNA), 3-hydroxykynurenine (3-HK), and 
anthranilic acid (AA)]. Many of the kynurenines display neu-
roactive properties. In particular, the neurotoxic metabolites, 
the N-methyl-d-aspartic acid (NMDA) receptor agonist and 
excitotoxin, QUIN, the free radical generators, 3-hydroxykynure-
nine (3-HK), 3-hydroxyanthranilic acid (3-HA), and the neuro-
protectants, picolinic acid (PIC), and KYNA, have significant 
associations with disease (19, 20), while the essential cofactor 
nicotinamide adenine dinucleotide (NAD+) is a very important 
end metabolite produced by catabolism of QUIN by the enzyme 
quinolinate phosphoribosyltransferase (QPRT).
TRiggeRiNg AgeNTS OF THe KP iN MS
Central nervous system inflammation and/or degeneration 
can trigger metabolism of TRP to produce kynurenine, and 
subsequent neurotoxic metabolites. Cells, such as monocytes 
and microglia, express all the KP components, whereas neurons 
express a restricted set and astrocytes lack expression of kynure-
nine 3-monoxygenase (KMO) resulting in high accumulation of 
kynurenine, a substrate for macrophages to further metabolize 
(12, 21–25). IDO-1 and TDO are the two enzymes that initi-
ate TRP metabolism (Figure 1) and are regulated by different 
mechanisms. TDO is induced by corticosteroids and glucagon 
(26), whereas IDO-1 is induced by proinflammatory cytokines 
during an immune response. The inflammatory mediators 
that activate KP through IDO-1 induction include interferon 
(IFN)-γ (20, 27), interleukin (IL)-1, tumor necrosis factor 
(TNF)-α (28), cytotoxic T lymphocyte-associated antigen-4 
(CTLA-4) immunoglobulin (29), toll-like receptor (TLR) (30) 
ligands polyinosinic:polycytidylic acid, lipopolysaccharide 
(LPS) (31), and unmethylated cytosine phosphatidyl guanosine 
(CpG) motifs (32). Although IFN-γ is regarded as the primary 
inducer of IDO-1, the regulatory mechanisms of IFN-γ medi-
ated IDO-1 induction can be potentiated synergistically by other 
proinflammatory cytokines, such as IL-1, TNF-α, IL-1β, and 
TLR agonists, resulting in synergistic enhancement of IDO-1 
expression (28, 33–36).
There is limited evidence that other enzymes within the KP 
can also be induced by proinflammatory cytokines, particularly 
by IFN-γ. Apart from the induction of IDO-1, IFN-γ is able to 
increase kynureninase (KYNU) activity in murine macrophages 
but not in microglial cells, which is of particular interest as 
TRP degradation by IDO-1 may not be the only enzymatic step 
controlling this pathway in activated macrophages (37). The 
enzyme diverting the KP toward the neurotoxic branch instead 
of KYNA production, KMO, is also increased through IFN-γ 
in activated macrophages (38) and in the brains of immune-
activated macaques (39). Finally, in the human hippocampal 
progenitor cells, IL-1β treatment increased KMO and KYNU 
transcript levels (40). At millimolar concentrations, PIC acted 
as a macrophage coactivator by inducing macrophage inflam-
matory proteins 1-α and 1-β in conjunction with IFN-γ in the 
induction of reactive nitrogen intermediate production (41–43). 
The complex interaction between PIC and IFN-γ highlights the 
importance of its involvement in inflammatory response (41) in 
neurodegenerative conditions. Interestingly, the current disease-
modifying agent of RRMS, IFN-β1b also induces KP metabolism 
in human macrophages and may be a limiting factor in its efficacy 
in the treatment for MS (21).
CSF: A wiNDOw TO STuDY 
DYSReguLATiON OF KP iN THe 
PATHOLOgY OF MS
Cerebrospinal fluid bathes the inner ventricles of the cortical 
subventricular zone (SVZ) and subarachnoid space. CSF is a 
complex mixture of water, secreted proteins, enzymes, antibod-
ies, peripheral blood, immune cells (e.g., B and T cell subsets), 
etc. and is constantly turned over, providing a sink for elimination 
of wastes from the interstitial fluid of the brain. This process is 
critical to proper brain homeostasis (44), and abnormal states 
are linked with multiple neurological diseases (45, 46). Choroid 
plexuses (47) are specialized structures located in the borders of 
the ventricles, facing the lateral wall, and consist of arrangements 
of epithelial cells (48), which secrete CSF and contain many villi 
which project into the ventricular space, vascular capillaries, 
neuronal contacts (49), and other supporting cells (Figure  2). 
Choroid plexuses, therefore, form a functional interface between 
the blood and CSF circulation and the bidirectional diffusion of 
important molecules, models of which are constantly evolving 
(50). Increasing evidence exists of alterations in choroid plexus 
function in various inflammatory CNS diseases (51).
From diagnostic, prognostic, and therapeutic aspects, CSF 
presents a unique opportunity to sample the content of fluid cir-
culating around the brain and cerebrovascular interfaces (52–56). 
For many years, we have utilized CSF from patients of various 
neurological diseases to assay for the concentrations of KP metab-
olites as a discrete compartment separate from the blood plasma 
(for which concentrations of KP metabolites are not an accurate 
measure of brain levels). Our standard techniques developed and 
improved over the years include analysis by sensitive methods, 
such as high-pressure liquid chromatography (HPLC) and gas 
chromatography-mass spectrometry (GC-MS), to determine KP 
metabolite levels (12, 14, 20, 21, 24, 25, 57–62). While analyses 
using these methods are extremely sensitive and able to accurately 
quantify KP metabolites in microliter-sized aliquots, due to BBB 
breakdown in MS (detailed further in Section “The BBB Performs 
a Critical Role in Maintaining Barrier Integrity and Permeability, 
Which Is Lost in MS”), the obtained data reflect the heterogeneity 
of such samples by influence of these factors and thus the extent 
of the pathology, and should be considered in concert with other 
pathological information. Furthermore, our previous study of 
brain microvascular endothelial cells (BBB endothelial cells) and 
pericytes uncovered that these cells express components of the 
KP that vary depending on the presence of inflammatory stimuli 
such as IFN-γ or TNF-α. After stimulation, both BBB endothelial 
cells and pericytes produced KYN that could potentially act as a 
substrate for the production of damaging KP metabolites in other 
neighboring cells (63). Other biomarkers within CSF related to 
MS pathology are also being progressively developed which 
would not be considered further here, e.g., Ref. (56, 64–66).
FiguRe 2 | Schematic summarizing the arrangement of cells within the choroid plexus and the physiology of exchange of solutes relevant to the 
understanding of how KP metabolites are found in CSF. From website http://jonlieffmd.com/blog/the-very-intelligent-choroid-plexus-epithelial-cell
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KP Metabolites Correlate with 
increased MS Severity: Potential 
utility as MS Biomarkers
In the EAE model of MS, significantly elevated levels of QUIN 
and the KYN/TRP ratio in rat serum were observed and these 
levels correlated with increasing disease severity (67). IDO-1 
expression was demonstrated to play a role in remission of acute 
MS in the EAE model, suggesting that the KP enzymes and 
metabolites could be involved in regulating disease course in MS 
(68). In patient samples, the first report of the potential involve-
ment of KP activation in MS pathology was several decades ago, 
when decreased levels of TRP were found in plasma and CSF of 
MS patients (69). This involvement was confirmed with numer-
ous subsequent studies showing alterations in KP metabolites 
in RRMS patients. These include evidence that patients showed 
decreased levels of neuroprotective KYNA in the CSF during the 
remission phase but became elevated during remitting, acute 
phases compared with healthy controls (70–72). While KYNA 
levels in humans are highly varying in concentration (73), an 
upregulation of KAT enzyme expression as a neuroprotective 
mechanism could be a possible explanation for this, hence more 
studies are needed.
Given that KP activation is modulated by proinflammatory 
factors including IFN-γ, it is expected that MS patients in the 
acute phase (compared with the later chronic neurodegenerative 
phase) exhibit CNS inflammation with greater involvement of 
KP metabolites in disease progression (1). A comprehensive 
study into the relation between several KP metabolites and 
neurocognitive symptoms is only now beginning to unravel the 
subtle distinctions in the subtypes of MS. RRMS patients show 
higher levels of QUIN in the relapse phase vs. during remission 
(74), suggesting that QUIN is a potential biomarker of active 
demyelination phases. Indeed, RRMS patients in remission did 
not show KP metabolite levels different from controls, suggest-
ing that kynurenine dysregulation is most prominent during 
symptomatic periods. Interestingly, PPMS showed increased 
concentrations of QUIN, TRP, and KYN, whereas SPMS had 
decreased levels of TRP and KYNA indicating that underlying 
pathogenic mechanisms that occur in PPMS may be distinct from 
those in SPMS. Notably, PPMS and the inflammatory control 
group (containing inflammatory disorders of the CNS) displayed 
similarities with amyotrophic lateral sclerosis, supporting the 
working hypothesis that alterations in KP metabolites are a 
common pathogenic mechanism across inflammatory diseases. 
Importantly, Hedegaard et al. has shown that MS patients sera, 
and not healthy controls, contain anti-myelin basic protein 
(MBP) autoantibodies that facilitate IFN-γ production (75). 
In line with this finding, a study examining changes in IDO-1 
activity and expression in peripheral blood mononuclear cells 
(PBMCs) of RRMS patients found high IDO-1 expression and 
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serum neopterin (a marker of inflammation) with a concomitant 
decrease in IFN-γ in the relapse phase of MS, but not in the stable, 
remitting phase of disease (76). This suggests that inflammation 
and KP activation are both mechanisms that are reflected in 
disease relapse and appearance of clinical signs. Current treat-
ments that aim to slow the progression of MS, including IFN-β 
1a and 1b and glucocorticoids, also alter KP metabolite levels. 
RRMS patients treated with IFN-β were found to have increased 
levels of neuroprotective KYN compared with untreated RRMS 
patients (77), whereas glucocorticoid treatment significantly 
reduced IFN-γ levels and IDO-1 expression.
THe BBB PeRFORMS A CRiTiCAL 
ROLe iN MAiNTAiNiNg BARRieR 
iNTegRiTY AND PeRMeABiLiTY, 
wHiCH iS LOST iN MS
The BBB and blood–cerebrospinal fluid barrier (BCB) are 
complex microvasculature barriers for the CNS and systemic 
circulation. These barriers provide protection, nutrient, and 
oxygen supply to the CNS. Under physiological conditions, 
the BBB (that surrounds parenchymal venules) and BCB (that 
surrounds the choroid plexus) protect the CNS from peripheral 
immune cell infiltration. The tight junctions (TJ) between the 
endothelial cells (of the BBB) and epithelial cells (of the BCB) 
restrict access of circulating cells to the CNS. Nevertheless, even 
in healthy brains, T cells can carry out immune surveillance of 
the CNS because they express adhesion molecules, chemokine 
receptors, and integrins that allow them to cross these barriers 
(78). On the other hand, the non-CNS targeted T cells are also 
capable of altering permeability and glial cell activity. Previous 
studies have shown that ovalbumin (OVA)-specific T cells are 
able to disrupt barrier integrity of the brain (79) and retina (80). 
Using an MRI approach, another group investigated in vivo T cell 
transmigration in relation to the BBB disruption on CNS tissues 
in a model using OVA- and proteolipid protein (PLP)-specific 
T cells, finding that antigen specificity (and not absolute number 
of infiltrating cells) is a critical determinant of the extent of BBB 
breakdown (81). Cerebral microvascular endothelial cells are also 
joined by TJ complexes with associated pericytes and astrocyte 
processes. During MS, damage of TJ proteins facilitates leukocyte 
infiltration, leading to oligodendrocyte death, axonal damage, 
demyelination, and lesion formation. Glial cell activation and 
further leukocyte invasion cause myelin damage and axonal deg-
radation. Production of cytokines worsens BBB damage leading 
to progressive disability (82).
The CP (Figure  2) is a highly vascularized brain structure 
located within brain ventricles and consists of an epithelial layer 
forming a tight BCB, surrounding a core of fenestrated capillaries 
and connective tissues. The fenestrated capillaries are surrounded 
by CP epithelial cells, which confer tight barrier properties and 
restrict the entry of immune cells in the CSF. A local impairment 
of the endothelial cells and chemokine production results in a 
reduction in barrier integrity of the BCB, which are prominent 
events for early invasion of immune cells into the CSF. Indeed, 
the presence of oligoclonal bands from B cells in Western blots 
from CSF is seen in ~90% of MS patients and is a common test 
for confirmation of MS diagnosis (52). After passing the BCB, 
CSF-infiltrated leukocytes produce large amount of cytokines 
and activate endothelial cells of the brain vasculature, inducing 
expression of adhesion molecules and chemokines, leading to the 
formation of inflammatory lesions (83).
BBB Breakdown and entry of 
immune Cells as a Key Hallmark 
of early MS Pathology
A damaged BBB allows infiltration of autoreactive T cells and 
monocytes into the brain parenchyma. In MS, leukocyte infiltra-
tion into the CNS parenchyma is one of the earliest hallmarks (80, 
84) and is thought to play a fundamental role in the development 
of the disease, including contributing to the early stages of lesion 
formation. BBB breakdown is also found in relapses (85–87); 
indeed, optic neuritis (ON) was the condition in which this was 
first noticed. Examination of the whole-mount retina preparation 
from EAE Lewis rats visualized the presence of BBB breakdown, 
cellular infiltration, and microglial activation as the earliest 
abnormal events in ON. This study also correlated the intensity 
of the immune response with the number of infiltrated leuko-
cytes and microglial activation in the retinal parenchyma (84). 
Inflammatory cells are found to predominantly colocalize within 
the disrupted BBB (88, 89). Activated inflammatory cells (ED1+ 
monocytes, CD4+, and CD8+ T cells) in the lumen of affected ves-
sels are capable of disrupting BBB permeability (84). Overall, these 
studies emphasize that abnormal BBB permeability and leukocyte 
infiltration in the CNS are key events leading to pathogenesis of 
MS. As discussed in greater detail in Section “Peripheral Blood 
Monocytes as a Potent Source of Inflammatory KP Metabolites 
in MS,” high expression of KP enzymes in activated monocytes, 
and their translocation into the brain parenchyma means they 
are poised to exert a profound impact on the survival of oligo-
dendrocytes and neurons, and hasten the progression of lesion 
development and MS pathology.
Although these previous studies have provided ample evi-
dence that BBB breakdown is the earliest event leading to MS 
pathology, these findings have been reinforced by modern MRI 
of the brain. For example, serial MRI studies have demonstrated 
that abnormalities of the BBB may precede myelin damage and 
leukocyte infiltration (90). Histopathological (91–94) and serial 
MRI (90,  95) studies indicated that structural changes may 
precede myelin damage and leukocyte infiltration. Cramer and 
colleagues use a sensitive dynamic contrast-enhanced (DCE) 
MRI concluded the importance of a BBB defect in MS. MS 
lesions are predominantly located in the periventricular nor-
mal appearing white matter (96, 97). The presence of ON and 
lesions can be predictive of MS progression, as an MRI-based 
risk stratification showed that patients with MRI T2 lesions and 
ON progressing faster to full MS compared with patients with 
ON alone (56 vs. 22%) (98).
Subsequently, Cramer and colleagues showed that the BBB 
permeability is able to predict conversion from ON to MS within 
2 years, in a group of patients presenting with monosymptomatic 
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ON- and T2-lesion count compared with another group presented 
with T2-lesion count alone (99). Subtle disruption to the BBB is 
often found at discrete locations in the brain, for which modern 
radiographical imaging modalities such as MRI can be utilized 
(100). Kawakami and Flugel also used intravital two-photon 
imaging to measure BBB permeability. Using this imaging tech-
nique, they examined infiltration of autoreactive T cells across 
the intraluminal surface of CNS blood vessels in animal model 
of MS (101).
KP iNFLueNCe ON THe 
iMMuNe SYSTeM
One of the most profound roles of the KP has been its implication 
in the pathological regulation of both the innate and adaptive the 
immune system (18, 102). IDO-1 is considered the major con-
tributor to the immunoregulatory functions of the KP due to the 
depletion of TRP and the production of kynurenine metabolites. 
IDO-1 is expressed in several types of immune cells, including 
microglia, monocytes, and macrophages, and can be readily 
induced by interferons, most effectively by IFN-γ (102). IDO-1 
activation has potent antimicrobial effects, which occurs partly 
through the depletion of the essential amino acid TRP. IDO-1 
plays a vital function in maintaining polymorphonuclear cells 
effector function against pathogens (103). Conversely, IDO-1 can 
also suppress the immune response leading to immunological 
tolerance, which mediates various phenomena such as allograft 
acceptance, tumor camouflage, and maternofetal tolerance (18).
To date, at least three mechanisms that initiate immunological 
suppression are known. These immunosuppressive effects all 
correspond to IDO-1 activation and its downstream effects in 
certain populations of T cells. First, TRP levels are depleted 
following IDO-1 induction, which inhibits the proliferation 
of reactive T lymphocytes and increases their susceptibility to 
apoptosis (104). Second, the resulting increase in kynurenine 
metabolites (KYN, QUIN, and 3-HAA) interferes with pro-
liferation and initiates selective apoptosis of T helper 1 (TH1) 
lymphocytes, which are responders to antigen-presenting cells 
(105, 106). Notably, there is a preferential inhibition for TH1 
cells by IDO-1 activation, although the activation of regulatory 
T-cells may also impede TH2 cells (102). There are contro-
versial data surrounding QUIN’s effect on T cell regulation, 
although it is currently thought that this process relies on a 
TRP-deficient microenvironment (105, 107, 108). KYN has been 
found to moderately impair the killing ability of natural killer 
cells, whereas KYN and 3-HAA both exert proapoptotic and 
suppressive effect on these cells (105, 106, 109). Additionally, 
TRP depletion and kynurenine metabolites act synergistically 
to downregulate expression of the T cell receptor ζ-chain on 
CD8+ T lymphocytes consequently reducing their cytotoxic 
capabilities (110). Third, the combination of the presence of 
kynurenine metabolites and TRP depletion increases the number 
of regulatory T cells positive for forkhead box P3 (FOXP3+) via 
TGFβ induction and its impact on naive T cells (110). Moreover, 
downstream TRP catabolites are able to shift dendritic cells to 
a tolerogenic phenotype independent of the microenvironment 
TRP levels, i.e., without functional IDO-1 (111, 112). Therefore, 
IDO-1 competent dendritic cells also contribute to KP-mediated 
immune-suppression by contributing to a tolerogenic environ-
ment. Together, this plays a substantial role in the development 
of immune tolerance and the induction of a negative feedback 
loop that regulates the immune response (113).
KP and immune Modulation 
in the Pathomechanism of MS
The importance of IDO-1 in immune modulation particularly to 
counteract autoimmunity has been illustrated in the EAE mouse 
model. Autoreactive CD4+ TH1 cells and TH17 cells mediate the 
autoimmune characteristics present in CNS inflammation in MS 
and in the EAE animal model (114). Indeed, there is widespread 
evidence that shows the potential of IDO-1 activation to reduce 
autoimmune inflammation in the CNS. Furthermore, pharmaco-
logical inhibition or genetic ablation of IDO-1 exacerbates EAE 
clinical scores, associated with decreased TReg cell responses and 
increased TH1 and TH17 responses (68, 115, 116). Conversely, the 
clinical symptoms of EAE can be ameliorated by administration 
of 3-HAA or its synthetic derivative, Tranilast, and are likely 
associated with an enhanced expression of TGFβ by 3-HAA. This 
possibly leads to an increase in the number of TReg cells, which 
can suppress the responses of autoreactive T cells, including the 
TH17 response (115). Furthermore, Xiao et al. reported that den-
dritic cells pretreated with IFN-γ alleviated the histopathological 
and clinical characteristics of EAE (117). It is hypothesized that 
IDO-1 activation is a self-limiting mechanism as both IDO-1 
and KMO are induced by the autoreactive, IFN-γ secreting TH1 
cells (37). This response could be designed to counteract the 
detrimental effects to the pathological elevation of kynurenine 
metabolites. This is supported by the observation of toxic levels 
of QUIN and 3-HK that are reached in the spinal cord but not the 
brain in EAE animals with concomitant increased activity and 
expression of KMO (67, 117, 118).
The neuroinflammatory process can be significantly decreased 
by inhibition of IDO-1 enzyme activity, considerably reducing 
disease exacerbation (119). Monaco et al. revealed corresponding 
clinical evidence of depressed TRP levels in both serum and CSF 
of MS patients (69). A subsequent study has yielded conflicting 
results to these findings, however, a negative correlation between 
neopterin, a marker of macrophage activity, and TRP levels in 
the CSF was observed, reflecting IFN-γ-induced macrophage 
induction and IDO-1 activation, respectively (120). Although 
an additional clinical study this year found an increase in IDO-1 
activation via QUIN/KYN ratios in MS patients compared with 
control, there were no significant differences in kynurenine 
metabolite levels between MS and other neuroinflammatory 
disorders. However, some patterns emerged upon stratification of 
disease into acute and chronic phases of disease course such as a 
high QUIN/KYN ratio in RRMS patients who are in relapse com-
pared with the remission phase. This suggests a high degree of 
variation in the course of neuroinflammation in MS (74). Initial 
IDO-1 activation is thought to be beneficial in MS; however, 
there is an emergence of a double-edged sword that is present 
following prolonged exposure. During CNS inflammation, 
FiguRe 3 | Passage of activated lymphocytes and monocytes across 
a compromised blood–brain barrier leads to dysregulation KP 
metabolism. Neurotoxic metabolites QUIN and 3-hydroxykynurenine are 
increased, while formation of neuroprotective kynurenic acid (KYNA) is not 
favored.
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increased IDO-1 activity generates kynurenine metabolites that 
are neuroactive, specifically neurotoxic QUIN (121). Therefore, 
although IDO-1 activation acts as an anti-inflammatory, its 
induction could contribute to the neurodegenerative features in 
MS in the long-term.
Peripheral Blood Monocytes as 
a Potent Source of inflammatory 
KP Metabolites in MS
Current evidence suggests that excessive activation of the KP in 
mononuclear phagocytes can participate in the pathogenesis of 
MS. Activated monocytes and monocyte-derived macrophages 
(MDMs) are abundantly present in the demyelinating plaques of 
MS patients and their migration from the periphery to the CNS 
is necessary for the development of the MS mouse model, EAE. 
Mononuclear phagocytes, in particular circulating monocytes 
and MDMs, display high levels of pivotal KP enzymes and can 
up regulate their expression in response to inflammation (23). 
Monocytes display considerable plasticity, being found in vari-
ous tissues and organs as resident macrophages, and patrolling 
forms with decreased expression of classical inflammation mol-
ecules (e.g., Ly6C in mice and CD14/16 in humans). Patrolling 
forms carry out immune surveillance of the endothelium and 
rarely extravasate into tissues without immune stimulus or tissue 
damage (122), in which case they are then alternatively regulated 
in classical inflammatory form [reviewed in Ref. (123)]. This 
makes them a potent source of neurotoxic KP metabolites (e.g., 
QUIN and 3-hydroxykynurenine) to contribute to MS pathology 
upon their migration and entry to the brain. Indeed, IFN-γ also 
caused upregulation of KMO and QPRT, two enzymes involved 
in the production of neurotoxic metabolites such as 3-HK and 
QUIN (12, 23).
Studies of the EAE model have reported a distinct rise in the 
level of Ly6Chigh proinflammatory monocytes within the blood 
stream before onset of clinical signs. At disease onset, or during 
relapses, proinflammatory monocytes migrate to the CNS, where 
their numbers directly correlate with the severity of EAE symp-
toms (124–126) and in turn, with elevated levels of neurotoxic 
QUIN in the spinal cord (67). This migration might be facilitated 
by a damaged BBB, one of the earliest clinical findings in MS, 
thought to play a fundamental role in the development of the 
disease [see BBB Breakdown and Entry of Immune Cells as a Key 
Hallmark of Early MS Pathology; Ref. (86, 87)]. To confirm that 
monocyte migration to the CNS is involved in EAE pathogenesis, 
Mishra and colleagues have demonstrated that its inhibition by 
the candidate MS drug Laquinimod prevented the onset of EAE 
and its clinical signs (126). More recently, depletion of phagocy-
totic monocytes by clodronate treatment reduced the severity of 
EAE symptoms and protected against further axonal loss (127).
In humans, early postmortem studies of MS plaques have cor-
related the number of macrophages present in chronic demyeli-
nating lesions to the severity of axonal damage responsible for the 
symptoms of the disease (128, 129). Indeed, monocytes have been 
found in acute demyelinating lesions and in the demyelinating 
edges of chronic lesions (130). Moreover, advanced microscopy, 
through 3D reconstruction of serial block-face scanning electron 
microscopy images, has been used in a pivotal study of EAE mice 
where Yamasaki and colleagues demonstrated that MDMs are 
directly in contact with the axoglial unit and begin demyelina-
tion, as opposed to microglia-derived macrophages that were 
only found adjacent to the lesions and participated in debris 
clearance (131).
The importance of this study and of the evidence linking 
activated mononuclear phagocytes to MS is highlighted by dif-
ferent lines of evidence about the KP in these cells: first, the 
activated MDMs produce 19 times more QUIN than activated 
microglia (23); second, the CNS-resident cells do not possess 
the full enzymatic machinery of the KP and are unable to 
synthesize high quantities of QUIN, but can still produce KYN 
(14, 22,  62); third, extra KYN released by astrocytes in the 
brain can be used by monocytes and MDMs that traffic into the 
brain to synthesize more QUIN (22); fourth, the level of QUIN 
produced by monocytes and MDMs is toxic to neurons and to 
oligodendrocytes (20, 132). Overall, this evidence suggests that 
monocytes and macrophages migrated to the CNS and activated 
by IFN-γ (133) can act as a major reservoir for the secretion and 
accumulation of damaging QUIN in the brain and spinal cord of 
MS patients. Therefore, this lends support to the possibility that 
monocytes and MDMs participate in the pathogenesis of MS via 
dysregulation of the KP and excessive accumulation of QUIN 
and associated neurotoxicity of oligodendrocytes and neurons 
(summarized in Figure 3).
MeCHANiSMS OF TOXiCiTY 
OF KP MeTABOLiTeS
Several decades ago, it was suggested that the kynurenines 
could act as important endogenous modulators and that they 
may be involved in the pathogenesis of not only MS but also 
a number of neurodegenerative diseases such as Alzheimer’s, 
psychological disorders such as schizophrenia and depres-
sion, and neuroinflammatory diseases such as HIV-associated 
neurological disorder (HAND) (57, 59–61, 134–137). Three 
kynurenines in particular, QUIN, 3-HK, and 3-HAA, were 
noted for their ability to cause in  vitro and in  vivo neuronal 
TABLe 1 | The mechanisms of toxicity following pathological increases in 
neurotoxic KP metabolites.
Metabolite Mechanism Pathology
3-HK ROS formation Oxidative stress, apoptosis, 
potentiation of excitotoxicity
QUIN Generation of free 
radicals, NMDA 
receptor activation
Excitotoxicity, free radical formation, 
mitochondrial dysfunction, apoptosis 
or necrosis, cytoskeletal destabilization
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death at slightly elevated concentrations. At low concentrations 
(≈50 nm), QUIN serves as a substrate for NAD+ production in 
neurons and astrocytes (132).
In pathological conditions, the concentrations of QUIN 
and 3-HK found in the CNS are significantly lower than the 
levels required to perturb neuronal survival (102). Rather, it 
is considered that these molecules become markedly potent 
neurotoxins during chronic exposure to low levels and those 
different populations of neurons are selectively affected by each 
agent (60). Chiarugi et  al. demonstrated that in murine mixed 
cortical cells, prolonged exposure to QUIN and 3-HK from 24 
to 72 h, significantly decreased neurotoxic thresholds from 100 
to 1 μM, respectively, and that exposure to a combination of the 
two compounds also increased the neurotoxic effects (138). This 
is of relevance to pathological conditions where both QUIN and 
3-HK are simultaneously released and concomitantly accumulate 
to levels that are neurotoxic leading to chronic exposure of CNS 
cells (7). QUIN neurotoxicity is primarily attributed to activation 
of the NMDA receptor and free radical production, and there-
fore shows complex patterns of neurodegeneration, while 3-HK 
and 3-HAA are accepted to have a primary role as pro-oxidant 
metabolites (Table 1) (138).
Quinolinic Acid
Under normal conditions, QUIN is present in nanomolar concen-
trations in the brain and is catabolized for the synthesis of NAD+. 
At low nanomolar physiological concentrations, QUIN is not toxic 
to neural cells; however, at elevated levels of QUIN (300 nM and 
possibly even as low as 100 nM with chronic exposure) that are 
found in inflammatory microenvironments, QUIN begins to be 
toxic (139). The pathological mechanisms of QUIN neurotoxic-
ity have therefore been found in numerous neurodegenerative 
processes associated with neuroinflammation such as MS.
Two major factors that render QUIN a potent neurotoxin 
is the saturation limit of QPRT, and QUINs ability to act as an 
endogenous weak agonist on the NMDA glutamate receptor. 
The 3-HAO enzyme, which produces QUIN, has an 80-fold 
higher reaction velocity than QPRT, the enzyme which degrades 
QUIN (140). Furthermore, neuronal QPRT is saturated at 
QUIN concentrations that exceed 500  nM (141). This leads to 
the production of QUIN at a faster rate than its conversion to 
NAD+, causing the accumulation of toxic QUIN- and NMDA-
mediated excitotoxicity (142). Furthermore, surrounding cells 
(astrocytes, neurons, and microglia) can take up excess released 
QUIN from the microenvironment, further promoting cellular 
damage. Moreover, astrocytes favor KYNA synthesis as they do 
not express KMO (25), whereas microglia preferentially form 
metabolites of the QUIN branch due to their low expression of 
KAT (102). Thus, astrocytes appear to maximize the synthesis 
of KYNA and alone are neuroprotective. However, it should be 
mentioned that it takes a threefold higher concentration of KA to 
antagonize the same amount of QUIN (143).
The low levels of QUIN in astrocytes are rapidly degraded. 
Indeed, the expression of QPRT by astrocytes is IFN-γ inducible 
and explains the rapid catabolism of QUIN in these cells (22). 
However, the presence of microglia or infiltrating macrophages, 
such as in MS, means that the high levels of KYN produced by 
astrocytes can be metabolized to QUIN by neighboring cells 
(Figure 4) (144). Low levels of neuroprotective PIC may also be 
synthesized in astrocytes, but production is severely compro-
mised by IFN-γ stimulation (25).
NMDA and excitotoxicity
Excitotoxicity is a pathological process that results in neuronal 
damage and death caused by the overactivation of excitatory 
amino acid receptors. Excitatory amino acids are the primary 
excitatory neurotransmitters in the hippocampus and cerebral 
cortex and thus play crucial roles in the psychological functions 
of neurons. Neuronal excitotoxicity typically refers to the exces-
sive exposure to glutamate, the major excitatory neurotransmitter 
in the CNS of mammals (145). QUIN is a selective agonist of 
NMDA receptors, specifically receptor subtypes are composed of 
NR2A and NR2B subunits. Therefore, as the hippocampus and 
striatum contain the widest distribution of NMDA receptors, 
they are areas of the brain most susceptible to QUIN neurotoxic-
ity. Interestingly, neural stem cells (NSCs) in the adult human 
brain are localized to the subventricular zone of the striatum and 
the subgranular zone of the hippocampus (146). Considering 
the importance of adult NSCs in migration and maturation into 
oligodendrocytes following demyelination in MS, their location 
in the regions of the brain that exhibit the highest levels of QUIN 
neurotoxicity, suggests a relationship between KP overactivation 
and the inhibition of remyelination in MS. In support of this 
concept, Croitoru-Lamoury et al. found that IFN-γ stimulation 
and concomitant KP activation in mesenchymal stem cells 
(MSCs) diminished their proliferation and altered their capacity 
to differentiate. Similar to MSCs, NSCs also express the complete 
and functional KP enzyme machinery (147). In addition, there 
is a plethora of studies that have demonstrated that QUIN, as 
well as KYN and 3-HA, have significant effects on proliferation 
and activation in specific T cell subsets (105, 107, 148). These 
studies indicate a key role of the KP in controlling proliferation 
and differentiation in various cell types. If pathophysiological 
concentrations of QUIN do affect NSC proliferation and dif-
ferentiation, it could provide a relevant mechanism by which 
remyelination is hindered in MS. Due to the rapid saturation of 
QPRT, the uptake of QUIN at the synaptic cleft can be delayed, 
causing further stimulation of the NMDA and continual damage 
(149). Prolonged activation of the NMDA receptors impairs cal-
cium homeostasis, generates free radicals through the activation 
of nitric oxide synthesis, and leads to mitochondrial damage and 
FiguRe 4 | Schematic summarizing the cytotoxicity mechanisms of QuiN in neural cells. This figure is taken from Ref. (149), under Creative Commons 
license. The significant effects of QUIN on oligodendrocytes have been summarized separately (see Oligodendrocytes Express Only a Subset of KP Enzymes and 
Oligodendrocytes Are Particularly Sensitive to Quinolinic Acid Toxicity).
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initiates programed cell death (150). This induced death has been 
observed at pathological concentrations in vitro with rat oligo-
dendrocytes (1  mM), primary human neurons and astrocytes 
(150 nM), and recently in motor neurons (100 nM) (132, 136, 
151, 152). There is additional evidence showing that QUIN can 
induce NOS activity in both neurons and astrocytes leading to 
increases in both poly(ADP-ribose) polymerase (PARP) activity, 
extracellular lactate dehydrogenase (LDH) activity, and oxidative 
stress through an increase in production of free radicals (149).
Quinolinic acid toxicity is also due to its direct effect 
upon the glutamatergic system, which potentiates its primary 
mechanism of excitotoxicity. In hippocampal slices and cultured 
astrocytes, QUIN has been shown to increase glutamate release 
in the synapses, inhibit its re-uptake, and reduce glutamate to 
glutamine recycling by inhibiting glutamine synthetase activity. 
This elevates synaptic glutamate concentration and potentiates 
excitotoxicity by further overstimulating the NMDA receptor 
(153–157). Therefore, chronic QUIN exposure is similar to the 
pathological effects seen in the neurodegeneration of MS. This 
is in agreement with the findings of Flanagan et al., who found 
a causal relationship between the degree of clinical severity in 
the EAE model and the levels of QUIN in the spinal cord (67).
Free Radical Production
N-methyl-d-aspartic acid receptor activation does not account 
for all of the neurotoxic effects mediated by QUIN. Indeed, 
oxidative stress and the generation of free radicals can occur 
through NMDA receptor-dependent activation or independently 
by the formation of QUIN–iron complexes. It has been shown 
that the QUIN–Fe2+ complex mediates the formation of reactive 
FiguRe 5 | The Fenton reaction for the production of reactive oxygen 
species.
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oxygen species (ROS) through the Fenton reaction (Figure  5) 
leading to downstream lipid peroxidation and in  vitro DNA 
damage (158).
This effect was attenuated when an alternative ligand for 
iron, the nucleoside analog acyclovir, was added. The removal 
of iron from QUIN inhibited lipid peroxidation and decreased 
the production of superoxide anion radicals demonstrating 
that the ligand identity is important to ROS development 
(159). Supporting this hypothesis, QUIN has also been shown 
to dysregulate redox homeostasis by affecting the endogenous 
antioxidants such as reduced glutathione, and depleting enzymes 
that scavenge free radicals, such as copper/zinc–superoxide 
dismutase (CuZn–SOD). QUIN has been shown to modify 
the activities of several endogenous antioxidants and deplete 
the activity of cytosolic CuZn–SOD, therefore exerting stress 
on primary antioxidant defense mechanisms (160). Moreover, 
these pro-oxidant effects of QUIN can be prevented by treatment 
with different antioxidants such as melatonin and pyruvate. The 
pro-oxidant toxicity of QUIN is likely to occur by decreasing 
the nuclear translocation of the transcription factor NF-E2-
related factor 2 (Nrf2), and important transcriptional activator 
of antioxidant response element (ARE). The Nrf2/ARE pathway 
induces phase II antioxidant enzymes and is therefore an impor-
tant promoter to detoxify oxidants. Tert-butylhydroquinone 
(tBHQ) exhibits antioxidant properties through its ability to 
induce Nrf2 nuclear translocation, thus activating ARE. In rat 
striatal slices, QUIN was observed to decrease nuclear Nrf2, 
while tBHQ protected against QUIN-induced mitochondrial 
dysfunction and lipid peroxidation, and partially recovered 
glutathione-S-transferase activity (161). This suggests that QUIN 
toxicity is also associated with a silencing of phase II antioxidant 
enzymes, thereby generating oxidative stress and simultaneously 
reducing antioxidant defenses.
In recent years, evidence implicates the roles of nitrative and 
oxidative damage and mitochondrial dysfunction in directly 
causing acute axonal damage in new inflammatory lesions in 
MS that may lead to degeneration (4, 162). An in  vivo study 
using confocal microscopy of early lesions in the EAE found free 
radicals caused early mitochondrial damage at inflammation 
sites prior to demyelination (163). Of interest, scavengers of 
reactive oxygen and nitrogen species could reverse this injury, 
indicating a potential neuroprotective strategy. It is thought that 
oxidative and nitrative damage advances both the initial and 
chronic active lesion in MS. Indeed, Haider et al. found that in 
active MS plaques and not in control brain tissue, there were 
high levels of oxidized lipids and DNA. DNA oxidation occurred 
mainly in oligodendrocyte nuclei, which also exhibited signs of 
apoptosis. Additionally, DNA and lipid oxidation correlated sig-
nificantly with inflammation, determined by quantifying human 
leukocyte antigen-D expressing macrophages and microglia and 
CD3+ T cells in the lesions (164). Given the key role of oxida-
tive damage in driving MS pathology, and QUIN-mediated free 
radical production, this could constitute an additional means by 
which the KP contributes to MS.
However, more recent reports have suggested a dual role of 
QUIN in being able to both scavenge and produce ROS, depend-
ing on the chemical environment and its concentration (165). 
Other small molecules that act as antioxidants, such as specific 
vitamins and metabolites, also typically show this double behavior 
and likely play a relevant role in maintaining redox homeostasis 
and oxidative balance. In support of this, studies have indicated 
that lower concentrations of QUIN affect the redox homeostasis 
of iron maintaining the Fe(II)/Fe(III) equilibrium (166). Indeed, 
it has been suggested that at low QUIN concentrations, QUIN 
participates as an antioxidant and that the combination of high 
levels of ROS and QUIN are required for oxidative stress and 
cytotoxicity (166). It should be noted that these experiments 
examined QUIN activity in non-cellular based assays. The com-
plex chemistry of QUIN will be largely milieu dependent and 
based on specific cellular environments.
Cytoskeleton
Quinolinic acid has also been shown to induce damage to den-
drites and axons with recent evidence showing that toxic QUIN 
levels phosphorylate structural proteins, thereby destabilizing the 
cytoskeleton (167, 168). The cytoskeleton is vital for neuronal cell 
shape and function and is involved in maintaining synapse for-
mation, internal transport of molecules, and neurite outgrowth. 
Furthermore, it has been well established that axonal injury, 
including axonal transport disruption, is prevalent in active 
MS lesions (169). Acute intrastriatal administration of QUIN 
was found to cause NMDA-mediated Ca2+ influx and oxidative 
stress that resulted in the hyperphosphorylation of intermediate 
filaments in neural striatal cells (149, 168). In rat striatal slices, 
100 μM QUIN altered the cytoskeletal homeostasis of both astro-
cytes and neurons. In astrocytes, QUIN’s actions were mediated 
by a rise in Ca2+ influx through L-type voltage-dependent Ca2+ 
channels (L-VDCC) and NMDA receptors, whereas in neurons, 
additional actions involved intracellular Ca2+ and metabotropic 
glutamate receptors. Both cases similarly result in a cascade of 
second messenger-dependent kinase activation, the phospho-
rylation of domain sites on neurofilament subunits and GFAP 
and irregular assembly of intermediate filaments in both glia and 
neuronal cells (167, 170, 171).
Additionally, work performed by Rahman et al. demonstrated 
that prolonged exposure to QUIN-induced significant changes 
to the structure of human neurons including decreasing orga-
nelles, dendritic beading, and the disruption of microtubules. 
The observed structural perturbations were associated with a 
decrease in major tau phosphatases expression and activity and 
consequently a concomitant increase in tau phosphorylation at 
multiple sites (168). In line with this evidence, Anderson et al. 
identified irregular tau phosphorylation in the EAE model and 
in progressive MS patients (169). Abnormal tau phosphorylation 
and insoluble tau accumulation is associated with both axonal 
and neuronal loss, which parallels the transition of relapse-
remitting to the chronic, secondary progressive stage in EAE. 
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Analysis of secondary progressive brain tissue in humans with 
MS revealed significant abnormal phosphorylated tau and 
insoluble tau formation. This observation was focused on areas 
dominated by demyelination, gliosis, and neuronal injury. Given 
that QUIN has direct effects on gliosis, neuron survival, and tau 
phosphorylation, this further supports a role for QUIN in the 
neurodegeneration associated with MS. Interestingly, QUIN 
may also have an effect on intracellular Ca2+ signaling as QUIN-
induced NMDA receptor overstimulation causes early damage to 
the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, 
thereby disturbing intracellular Ca2+ regulations (172).
3-Hydroxykynurenine
Similar to QUIN, the plasma, brain, and spinal cord levels of 3-HK 
are elevated in EAE rats (118). There is evidence that 3-HK is a 
neurotoxic metabolite and it, therefore, may have an important 
role in the neurodegeneration of MS (173). To date, there is a mul-
titude of literature providing evidence that 3-HK is a pro-oxidant 
and a potent generator of reactive species that induces apoptosis. 
This characterization has been performed in vitro at concentra-
tions that are supraphysiological, ranging from 10 μM to 1 mM. 
These concentrations are considerably higher than both normal 
brain (~0.08–0.3 μM) and pathological brain (0.3–1.2 μM) con-
centrations and could evoke toxicity not observed under normal 
conditions (113). In support of this, there is growing evidence 
suggesting that 3-HK is an endogenous antioxidant. Despite these 
considerations, 3-HK is described as neurotoxic and the dual 
effects of this metabolite will be discussed below.
In the presence of oxygen and at neutral pH, 3-HK easily 
undergoes auto-oxidation forming o-semiaminoquinone. The 
oxidation of 3-HK has been found to (1) generate ROS, which 
promotes lipid oxidation, protein modification, inflamma-
tory response modulation, and DNA damage; (2) reduce trace 
transition metals, including Fe3+ and Cu2+, to pro-oxidants, Fe2+ 
and Cu+, capable of generating further radical formation in 
Fenton-like reactions; (3) o-semiaminoquinone readily reacts 
with oxygen generating quinone-imine, another highly reactive 
product which also participates in additional oxidative reactions 
(113). In line with this, 3-HK and 3-HAA (10  μM) induced 
neuronal cell death with apoptotic features following generation 
of ROS in primary striatal neurons. This toxicity was dependent 
on its cellular uptake by large neutral amino acid transporters 
in a sodium-dependent process and the increase in intracellular 
ROS, as various antioxidants inhibited this process (174, 175). 
Cell death occurred via p38 death signaling and was independent 
of caspase-3 mechanisms. However, cerebellar granule neurons 
appeared more resistant than striatal cells to HK-induced dam-
age, suggesting toxicity specificity (250 μM) (176, 177).
Interestingly, when human astrocytes are treated with 3-HK at 
concentrations lower than 100 nM, intracellular NAD+ levels are 
significantly augmented. At doses above 100 nM, however, NAD+ 
levels are significantly decreased and extracellular LDH activity is 
increased (178). NAD+ is a molecule involved in many metabolic 
processes and is a vital cofactor for several enzymes. For example, 
NAD+ is a precursor for agents that mobilize calcium and regu-
late gene transcription through chromatin-associated protein 
modification and is a substrate for ADP ribosylation of proteins 
(179, 180). Therefore, alterations in 3-HK concentrations may 
indirectly change (1) gene expression, (2) DNA repair, and (3) 
intracellular Ca2+ levels.
There have been few studies of the in  vivo effect of 3-HK. 
Of these, the most notable examined the synergistic possibility 
of the combination of 3-HK and QUIN in neurotoxicity. In rat 
brains, intrastriatial injection of 3-HK (5 nM) or QUIN (15 nM) 
individually caused no or marginal damage, whereas coinjection 
of the two metabolites caused impaired rotational behavior and 
significant increases in the volume of lesions (113). Notably, 
there was an absence in de novo generation of QUIN suggest-
ing that the in  vivo conversion of QUIN from 3-HK was not 
the mechanism behind the potentiation of QUIN toxicity (181). 
This could be a result of coinjection, as there is a possibility of 
chemical interactions that could modify the reactive components 
of each reagent (113). These findings might also indicate that 
the normal brains capacity to scavenge radicals is sufficient to 
counteract 3-HK-induced radical formation and prevent cellular 
apoptosis (182).
3-HAA
At present, there have been several studies that have examined 
3-HAA activity in conjunction with 3-HK. It has been recognized 
that 3-HAA exhibits similar characteristics to 3-HK to generate 
superoxide anions by undergoing auto-oxidation and, thus, 
initiate apoptosis (183). Recent evidence has also indicated that 
3-HAA has immunomodulatory roles that could play important 
roles in MS (184). This emerging evidence is discussed in Section 
“KP Influence on the Immune System” above.
OLigODeNDROCYTeS AS A TARgeT 
CeLL FOR eLevATeD LeveLS OF KP 
MeTABOLiTeS iN MS
Oligodendrocytes are demyelinated and perish in MS most prob-
ably through the action of autoimmune T cells and associated 
neuroinflammation. As there is substantial influx of immune 
cells into the brain in MS, a significant body of evidence exists 
supporting a dysregulated KP in MS, which can favor the pro-
duction of neurotoxic metabolites which further compromise 
oligodendrocyte health and function and could also contribute to 
neuronal atrophy. The known studies investigating the presence 
of KP metabolites and/or KP action on oligodendrocytes in MS 
are discussed below.
Oligodendrocytes express Only a Subset 
of KP enzymes
Overall, while oligodendrocytes express several KP enzymes and 
may be able to uptake certain KP metabolites and participate 
in their metabolism, they appear not to express IDO-1, mean-
ing that they are incapable of modulating T cell phenotype and 
KP action by metabolizing TRP. Radiolabeled QUIN was not 
detected in rat brain cultured oligodendrocytes after IFN-γ 
stimulation and incubation with radiolabeled TRP (185), lead-
ing to the subsequent conclusion following the study of human 
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primary oligodendrocytes that oligodendrocytes are not capable 
of synthesizing QUIN de novo, rather they metabolize it (62). Via 
PCR, we demonstrated that IDO-1 is not expressed in human 
primary oligodendrocytes, even with IFN-γ stimulation (62), 
though data on adult oligodendrocytes are currently lacking. 
The enzymes tryptophan-2,3-dioxygenase (TDO) and kynure-
nine amino transferases II (KATII) were also not expressed, 
while KAT-I and enzymes further down the KP [KYNU, KMO, 
3-hydroxyanthranilate oxygenase (3-HAO), and QPRT] were 
expressed, and increased in expression with IFN-γ stimulation.
The oligodendrocytes constitutively express the QPRT 
enzyme shows that they have the enzymatic machinery for fur-
ther metabolism of QUIN to the essential cofactor NAD+ (62). 
QPRT was only modestly increased in expression in human oli-
godendrocytes in response to IFN-γ stimulation (62), suggesting 
that in inflammatory environments it could be easily saturated 
(considered further in Section “NMDA and Excitotoxicity”). 
Clearly, with regard to oligodendrocytes, the expression of QPRT 
and function in disease requires further study. Oligodendrocytes 
can also produce the neuroprotective PIC at concentrations of 
45–55 nM [depending on whether IFN-γ stimulus is present (62)]; 
intriguingly, this was present at substantial (≈10-fold) excess 
compared with QUIN (even with IFN-γ stimulus) suggesting the 
predominant balance of the metabolism of the common QUIN/
PIC precursor α-amino-β-carboxymuconate-ε-semialdehyde 
(ACMS) is skewed toward PIC production, or alternatively, that 
excess QUIN in oligodendrocytes is rapidly converted to NAD+ 
via QPRT. Our recent experiments in cultured oligodendrocytes 
[Ref. (20) and discussed in Section “Oligodendrocytes Are 
Parti cularly Sensitive to Quinolinic Acid Toxicity] currently do 
not support the latter hypothesis. The presence and function 
of 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase 
(ACMSD) in oligodendrocytes is unknown at present, although 
from other studies its enzymatic activity is known to be partially 
inhibited by KYNA, QUIN, and PIC (186).
Oligodendrocytes Are Particularly 
Sensitive to Quinolinic Acid Toxicity
Quinolinic acid is an NMDA receptor agonist and excitotoxin 
(139, 187), and oligodendrocytes are susceptible to NMDAR-
mediated excitotoxicity with subsequent alterations to Ca2+ and 
other intracellular signaling that culminates in apoptosis (151, 
152, 188–190). Therefore, in the context of activated monocyte 
influx during inflammatory demyelination episodes and secretion 
of QUIN, excitotoxicity induced by QUIN on oligodendrocytes 
is a major consideration in the progression of MS pathology. 
Conventional MS treatments can reduce the frequency of inflam-
matory episodes but do little to counteract the demyelination and 
death of oligodendrocytes (191).
Activated monocytes can enter the brain during BBB break-
down events and secrete QUIN or activate KP in neural cells by 
secretion of IFN-γ. Exposure of oligodendrocytes to excitotoxic 
QUIN at high levels, therefore, constitutes a further insult in 
concert with autoimmune-mediated demyelination. Indeed, we 
recently demonstrated by microscopy that QUIN can be rapidly 
taken up in vitro by cultured oligodendrocyte cell lines (substantial 
uptake was observed within 30–90 min), without significant deg-
radation of QUIN. One possibility for the enhanced uptake is that 
the QPRT enzyme responsible for further metabolism of QUIN 
is saturated at a lower concentration, and hence in inflammatory 
circumstances QUIN accumulates in oligodendrocytes similar 
to that observed in neurons that are associated with Alzheimer’s 
pathology (168).
More importantly to MS pathology, these cells were also very 
sensitive to QUIN toxicity, which induced apoptotic cell death 
(LD50 0.5–1.0  μM in oligodendrocyte cell lines) (20). This is 
supported by the findings of others (151, 152). Apoptosis could 
be completely reversed by treatment with a monoclonal block-
ing antibody recognizing QUIN or by the use of specific IDO-1 
enzyme inhibitors (to abolish QUIN production in monocyte-
lineage cells) (20). In addition to QUIN concentration, chronicity 
of exposure and cell type is likely additional determinants of exci-
totoxic effects on brain cells. In the context of an inflammatory 
microenvironment, T-cell-induced damage to the myelin sheath 
as well as the toxicity induced by the presence of elevated levels of 
monocyte-produced QUIN are likely to significantly contribute 
to apoptosis of oligodendrocytes observed in MS.
Oligodendrocytes express multiple types of glutamate 
receptors, including N-methyl-d-aspartate (NMDA), alpha-
amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), 
and kainate. In white matter ischemic damage, excitotoxic cell 
death  of oligodendrocytes via AMPA and kainate receptors 
are  most often implicated (190, 192, 193). Oligodendrocytes 
lacking glutamate receptor subunit 2 (GluR2) are susceptible to 
AMPA/Kainate-induced excitotoxicity (190, 194). Spinal gray 
(195) and the myelinating processes of white matter oligodendro-
cytes express some NMDA receptors (188, 189, 196). Subsequent 
work confirmed that oligodendrocytes have an unusual NMDA 
receptor composition compared with neurons or other cells (197). 
Oligodendrocytes do express NR2A and 2B subunits (188), which 
have been confirmed in Xenopus oocytes to bind and be activated 
by QUIN, while NR2C subunits have 10-fold less affinity (198).
Although there is evidence that blockade of NMDA receptors 
is neuroprotective in inflammatory CNS diseases, and indeed can 
improve survival of oligodendrocytes (199, 200), future therapeu-
tic use of this strategy needs to be tempered with an understand-
ing that a “one-size-fits-all” approach such as broadly targeting 
NMDA receptors may not result in complete neurological disease 
resolution, and indeed, could have substantial side-effects includ-
ing effects on other cell types such as neurons (201, 202). Hence, 
in our opinion, there is a clear notion that understanding the role 
of the KP in immune modulation and production of neurotoxic 
metabolites with action on oligodendrocytes could lead to the 
generation of alternative kinds of targeted therapies, which may 
be used as novel treatments for MS and possibly other autoim-
mune diseases.
MODuLATiON OF THe KP AS A 
THeRAPeuTiC STRATegY iN MS
Many therapeutic strategies are currently being pursued to protect 
against dysregulated KP metabolism in neurological diseases 
FiguRe 6 | Potential therapeutic targets for the modulation of the kynurenine pathway. Dashed boxes indicate pharmacological analogs, whereas crosses 
indicate inhibitors.
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[summarized in Ref. (203)]. In the context of MS, current treat-
ments are anti-inflammatory and although they effectively reduce 
the number and duration of relapses they do not appear capable of 
preventing long-term disability and mortality (204). This demon-
strates an obvious lack of therapies that target the neurodegenera-
tive components of the disease and that facilitate remyelination. As 
the KP is highly implicated in the pathophysiology of neurodegen-
eration and neuroinflammation, KP enzyme inhibitors together 
with kynurenine metabolites and their pharmacological analogs, 
could represent promising new therapeutic strategies that could 
target these mechanisms. A synthetic analog of the TRP metabolite 
N-[3,4-dimethoxycinnamoyl]-anthranilic acid (3,4-DAA), known 
commercially as Tranilast, has shown promising results in both 
in vivo and in vitro experiments (Figure 6).
Hertenstein et al. found that 3,4-DAA inhibited CD4+ T cell 
activation and proliferation and naive CD8+ T cells, although 
to a lesser extent (205). EAE animals treated with 3-HK or its 
synthetic derivate, Tranilast, showed reduced symptoms, number 
of relapses, and fewer inflammatory nodes in the spinal cord and 
brain (115, 206). In the EAE mouse model, the activity of KMO is 
significantly increased in spinal cords and this correlates with an 
increase in QUIN and 3-HK to neurotoxic levels. Administration 
of the KMO inhibitor Ro 61-8048 reduced the rise in levels of both 
QUIN and 3-HK, increased neuroprotective KYNA production 
and significantly alleviated disease progression (118). A number 
of immunomodulatory drugs such as leflunomide (the active 
metabolite is Teriflunomide) and Laquinimod, are structurally 
analogous to KYN and KYNA, respectively, and exhibit immu-
nosuppressive properties by promoting a TH2 profile through a 
shift in cytokine balance and inhibiting activated T cells. These 
drugs were shown to ameliorate disease in EAE and Teriflunomide 
passed phase III clinical trials and is currently approved by the 
FDA. Although Laquinimod demonstrated only modest effects on 
the relapse rate in RRMS in phase III trials, it showed significant 
reductions in brain atrophy and is currently in phase III trials for 
PPMS, in which there are currently no approved disease-modify-
ing treatments (207, 208). Together, the immunomodulatory and 
structural similarities of these drug candidates to kynurenines 
strongly implicate kynurenine analogs as novel and intriguing 
therapies for MS. The concept of KP therapies in MS is further 
supported by in  vitro findings that QUIN is toxic to oligoden-
drocytes. Importantly, inhibiting IDO-1 (1-MT or berberine) or 
neutralizing QUIN directly with anti-QUIN antibodies overcame 
the toxicity toward oligodendrocytes that QUIN displayed (20).
Given that QUIN is present at pathophysiological concentra-
tions that correlates with severity in EAE mice, manipulations 
that directly modulate its concentration-such as inhibition of 
IDO-1 or KMO are of considerable interest. However, systemic 
inhibition of IDO-1 has been demonstrated to exacerbate disease 
in EAE mice (18). This is due to the double nature of IDO-1 
activation, where initial activation is immunosuppressive and 
is an important mechanism to counteract the autoimmune 
response; however, prolonged activation leads to the production 
of neurotoxic and oligotoxic kynurenines, thereby contributing 
to the pathology of MS. It is, therefore, likely that the timing of 
intervention is important. It is clear through both experimental 
and indirect evidence that the complex anti-inflammatory and 
neuroprotective properties of the KP metabolites have a funda-
mental link with MS. This warrants screening of these candidate 
drugs and highlights their therapeutic potential in MS.
FiguRe 7 | Plasmodium-primed CD8+ T cells induce monocyte 
accumulation in Macgreen × RAg−/− mice. PbA-infected 
MacGreen × RAG−/− mice that had received primed CD8+ T cells underwent 
intravital imaging on day 7 p.i. (n = 3 mice/group). Representative snapshot 
shows severe levels of monocyte accumulation in the blood vessels. Scale 
bar represents 60 μm. Migratory paths of monocytes are shown as purple 
tracks. Blood vessels are marked by infusion of TRITC-conjugated dextran. 
White arrows indicate direction of blood flow. Data are a mean of two to three 
independent experiments [figure reproduced from Ref. (215), under Creative 
Commons Attribution license].
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MiCROSCOPe iMAgiNg AS A CeNTRAL 
TOOL FOR ADvANCiNg KNOwLeDge 
OF MS PATHOLOgY
This review has discussed (particularly in Sections “The BBB 
Performs a Critical Role in Maintaining Barrier Integrity and 
Permeability, Which Is Lost in MS” and “Peripheral Blood 
Monocytes as a Potent Source of Inflammatory KP Metabolites 
in MS”) the significant achievements which have been generated 
by the use of imaging technology in MS studies, particularly non-
invasive imaging such as MRI, and also correlative microscopy 
and histopathology. For mouse models of MS, multiphoton 
microscopy (Figure 7) has traditionally been the imaging tech-
nique of choice for imaging intact thick tissue sections (>200 μm) 
(209–212). Additionally, the easy availability of intravital imag-
ing technology has greatly expanded the opportunity of directly 
observing the spatio-temporal context in which inflammatory 
events unfold in  situ within the natural microenvironment of 
the CNS (213–215). Therefore, it is fast becoming the preferred 
modality for analyzing neuroinflammation in vivo. The advent of 
highly streamlined surgical protocols used in combination with 
two-photon intravital microscopy (2P-IVM) has proven to be 
powerful for characterizing the cellular and molecular mecha-
nisms that underlie neuroinflammation (216–218). Its applica-
bility across a breadth of neurological disciplines have helped 
identify novel routes of immune cell entry, their locomotion 
patterns, intravascular and transendothelial migration, homing, 
interactions with endothelial, immune, stromal, and neuronal 
cells, among others (219–223). These studies have significantly 
increased our understanding of the initiation and perpetuation 
of inflammation within the CNS and laid an excellent platform 
for making further advances within the field.
Our knowledge of how immune cells are recruited to the CNS; 
navigate through the CNS tissue; respond to self-antigens, patho-
gens, toxic metabolites, etc., and how they contribute to inflam-
matory diseases has been greatly informed by intravital imaging 
studies on EAE, one of the most intensely studied animal models 
of MS (224–228). In the past, EAE studies have been limited by 
the requirement for sophisticated imaging tools that can track 
T cell entry, behavior, and transmigration at cellular and subcel-
lular resolution within the CNS. The complexities of tracking 
T cells in the CNS are related to the unique anatomical barriers 
such as the BBB that partly seclude the CNS from the constantly 
changing microenvironment of the blood stream, and its circulat-
ing immune cells (78, 229, 230). 2P-IVM (fluorochrome excited 
by two photons of 976 nm wavelength) circumvents some of these 
limitations due to its twin advantages of low phototoxicity and 
photobleaching, which enable long-term visualization (~1.5–6 h) 
and better penetrance (250–300 μm) of the CNS tissue (216).
Two-photon intravital microscopy studies have revealed 
that TMBP cells (T cells recognizing oligodendrocyte MBP) first 
appear in the CNS vasculature during the build-up to EAE (225). 
Although it was not possible initially to ascertain the precise 
location of the infiltrating TMBP cells using video microscopy, it is 
now clear that ~80% of the infiltrating TMBP cells arrest and then 
crawl along the inner surface of the vessel wall soon after their 
entry (101). Only TMBP cells that carry specific molecular signa-
tures such as VLA-4 transmigrate through the BBB where they 
spend 80% of their time crawling once again on the abluminal 
surface of the vasculature, before detaching and crawling finally 
on the surface of the neuropil (224, 225). Therefore, infiltrating 
TMBP cells crawl along three different cellular planes at different 
velocities with the end objective of “seeking” and contacting 
perivascular macrophages (PVM) that reside in the perivascular 
space (101, 231).
Real-time imaging studies have shown that after gaining pas-
sage into the perivascular space, TMBP cells make short or long-
lasting contact (>10  min) with PVM, antigen-presenting cells 
that strategically line blood vessels and monitor the environment 
with thin, motile cellular processes (209, 225, 232). Polarization 
of TCR and adhesion molecules such as LFA-1 as well as 
nuclear translocation of fluorescent NFAT, indicative of calcium- 
dependent T cell activation have been reported to occur at these 
contact points (227, 233). Interestingly, perivascular microglial 
and PVM clustering is one of the first pathological alterations 
that occurs in response to BBB disruption, during the build-up 
to EAE (234). As part of this alteration, cell body motility and 
process extension of microglia and PVM are specifically directed 
toward the affected vasculature where BBB disruption occurs. 
Thus, PVM clustering may only serve to enhance the chance of 
TMBP cells encountering cognate antigen and invading the CNS 
parenchyma, besides its reported contribution to axonal damage.
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Studies have shown that a majority of the TMBP cells that invade 
the CNS parenchyma meander through the tissue (233). A small 
number exhibited confined motility, reminiscent of cells that 
have found cognate autoantigen. At first glance, these TMBP cells 
appeared stationary; however, closer examination showed that 
they were remarkably agitated, rapidly extending and retracting 
cell protrusions and migrating at very low velocities through the 
tissue. Expectedly, extended recordings spanning several hours 
were necessary to resolve these fine locomotion patterns of TMBP 
cells at the single cell level, especially since the sum of their 
directionality and length of migration remained close to zero 
(101, 233).
Despite the increasing number of real-time multiphoton 
studies that have yielded tremendous insights into the behavior 
of T cells in the processes leading to lesion formation at the single 
cell level in mouse MS models, application of this technology 
to the study of monocytes has yet to emerge. As described in 
Section “Peripheral Blood Monocytes as a Potent Source of 
Inflammatory KP Metabolites in MS,” evidence supports a role 
of activated monocytes in production of neurotoxic metabolites, 
which could contribute to MS pathology. Therefore, future 
studies to understand the behavior of monocytes as they pass 
into the brain parenchyma and interact closely with cells such as 
oligodendrocytes will provide additional insight to those gained 
recently by serial block-face reconstruction ultrastructure imag-
ing (131).
SuMMARY AND CONCLuSiON
Imaging is now a central tool in MS research and treatment, 
allowing clinicians to evaluate the extent of the pathology and 
effectiveness of treatments while microscopy advances have 
allowed us to, in the case of multiphoton microscopy, peer deep 
into the brain to uncover mechanisms involved in immune cell 
trafficking and BBB dysfunction. Electron microscopy advances 
have also allowed automated processing and imaging of slices of 
tissue sections, allowing the ultrastructure of cell–cell interac-
tions in MS to be confirmed. While MS is traditionally thought 
of in the context of aberrant autoimmune triggering of T cells, 
the multifaceted nature of the disease has emerged through 
increasing evidence of neurodegenerative pathology and the 
involvement of other cell types such as monocytes, and in turn 
signaling systems including the KP. This increasing recognition 
has led to the current notion of MS as involving a substantial 
degenerative disorder component (9). In this context, over the 
past two decades, a substantial body of literature has proven that 
dysregulation of the KP results in overproduction of neurotoxic 
metabolites that can potently kill brain cells. In MS, the extent of 
the pathology and disease progression correlates with elevated 
levels of neurotoxic metabolites which can contribute to the 
death of myelinating oligodendrocytes and their neighboring 
neurons, including during autoimmune inflammatory episodes. 
Therapeutic interventions to reduce the levels of damaging KP 
metabolites and improve oligodendrocyte and neuron survival 
are in continual development and progress toward clinical 
utility.
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